Home | Life Sciences Intellectual Property Review
WEBSep 19, 2024 · The court rejected the medical device company’s auxiliary requests and nixed patent in 17 territories although it seems receptive to these amendments in general, say Laura Orlando and Rachel Montagnon of Herbert Smith Freehills.
Latest News & Features | Life Sciences Intellectual Property Review
WEBSep 19, 2024 · The court rejected the medical device company’s auxiliary requests and nixed patent in 17 territories although it seems receptive to these amendments in general, say Laura Orlando and Rachel Montagnon of Herbert Smith Freehills.
CRISPR | Life Sciences Intellectual Property Review
WEB9 November 2020 The European Patent Office has released the long-awaited reasoning for its decision to uphold the revocation of a Broad Institute CRISPR/Cas9 patent. In January this year, the EPO’s Board of Appeal concluded that the Broad’s patent, EP2,771,468, lacked novelty due to an invalid claim to priority.
'This is a big problem’: The CRISPR controversy and the ‘mess’ at …
WEB18 hours ago · A request by CRISPR scientists to withdraw their patents over allegations of mishandling by the EPO’s Boards of Appeals has thrust a ‘fundamentally unfair, uncertain system’ into sharp focus, finds Sarah Speight.
Americas | Life Sciences Intellectual Property Review
WEB13 February 2024 US Patent and Trademark Office publishes ‘clear’ guidance mandating AI-related patents to have ‘significant’ human involvement | Cites one hypothetical example relating to the development of a compound for treating cancer | Kathi Vidal: ‘patent system was developed to incentivise and protect human ingenuity’.
Unified Patent Court | Life Sciences Intellectual Property Review
WEBA distinctive UPC approach to patent validity and revocations is emerging as the court shows its willingness to break new ground, say Emily Bottle and Sebastian Moore of HSF. Signs show that an uptick of life sciences cases at the Unified Patent Court is likely, but does the court have capacity ...
Generics | Life Sciences Intellectual Property Review
WEBGeneric drug makers are watching two cases that will determine whether pharmaceutical firms can deduct—rather than capitalise—legal fees for defending against patent infringement suits, say Carina Federico and Anne Li of Crowell & Moring.
Interview: Klaus Grabinski, UPC Court of Appeal president
WEB3 days ago · 9 September 2024 UPC clarifies that evidence must show that pre-launch preparations are complete for threat of imminent infringement to occur | Question remains over how the UPC will deal with the cumulative activities of several companies in a group | Court also broaches key cross-border question.
The future of precision medicine part 1: challenges and …
WEBThe promise of precision medicine has been extolled by researchers and clinicians for some time, but as sequencing costs continue to fall, sophistication of data analysis and patient …
Medtech | Life Sciences Intellectual Property Review
WEB26 March 2024 Judge’s dissenting opinion challenges the interpretation of the safe harbour provision by the US Court of Appeals for the Federal Circuit | Decision concerns Meril's importation of transcatheter heart valve systems in a dispute with Edwards Lifesciences | Court majority upheld the district court's ruling favouring Meril.